35th week of 2008 patent applcation highlights part 58 |
Patent application number | Title | Published |
20080207523 | COMPOUNDS AS APTAMER-DIMERS AND THEIR USES IN DIAGNOSIS AND THERAPY - The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent. | 2008-08-28 |
20080207525 | IAP BIR domain binding compounds - Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II | 2008-08-28 |
20080207526 | Synthetic peptides and methods of use for autoimmune disease therapies - The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein. | 2008-08-28 |
20080207527 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof - The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. | 2008-08-28 |
20080207528 | HCV PROTEASE INHIBITORS - This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection. | 2008-08-28 |
20080207529 | Isolated Dipeptides with Ace Inhibitor Effect - Use of a preparation comprising an isolated peptide selected from the group consisting of: Leu-Val (LV) (SEQ ID NO: 1) and lie-Val (IV) (SEQ ID NO: 2) for the preparation of a composition having angiotensin-converting enzyme (ACE) inhibitor effect. The peptides may e.g. be used to make a functional food with anti-hypertensive properties. | 2008-08-28 |
20080207530 | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs - The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor. | 2008-08-28 |
20080207531 | Novel Milk Protein Fractions and Use Thereof For Preventing or Treating Chronic Inflammatory Diseases - The invention concerns TGF-β-enriched milk protein fractions, a method for preparing same and use thereof for preparing a medicine and/or a food composition for preventing and/or treating chronic inflammatory diseases, and in particular psoriasis. | 2008-08-28 |
20080207532 | Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection - Compositions and methods for using nordihydroguaiaretic acid (NDGA) derivatives for preventing the expression of MDR-1 gene and the synthesis of PgP protein or reversing multiple drug resistance in cells, and for using NDGA derivatives in combination with additional chemotherapeutic agents to treat drug resistant cancer and infections. | 2008-08-28 |
20080207533 | Pharmaceutical Compositions - A pharmaceutical composition and granulates, prepared by a wet granulation process. The pharmaceutical composition and granulates contain a therapeutic compound, e.g., the 3′-L-valine ester of β-D-2′-C-methyl ribofuranosyl cytidine and its salts, esters, prodrugs or derivatives. | 2008-08-28 |
20080207534 | 1,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMIC - The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic. | 2008-08-28 |
20080207535 | Method of attaching drug compounds to non-reactive polymer surfaces - Polymers are disclosed that are chemically modified to retard bacterial growth. Such modified polymers (e.g. ePTFE and polypropylene) are produced by first creating acid groups on the polymer surface through reactions with an anhydride. The acid groups are then linked to polyethylene glycol (PEG) through esterification or other reactions such as amidation. Preferably, at least two different molecular weight PEG species are employed. The antimicrobial surface is completed by linking antibiotics (e.g. β-lactam antibiotics) to the PEG extensions. One preferred embodiment of such a modified polymer is produced using ePTFE, maleic anhydride (MA), and penicillin (PEN) to yield PEN-PEG-MA-ePTFE, which inhibits gram-positive bacteria. The PEG spacer is critical for PEN function in this context, since PEN-ePTFE is ineffective against bacterial growth. Another preferred embodiment incorporates ampicillin (AMP) and a heterobifunctional PEG, HOOC—(CH | 2008-08-28 |
20080207536 | Antibacterial Agents - The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against bacterium such as | 2008-08-28 |
20080207537 | Topical Ungual Formulations - Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail. | 2008-08-28 |
20080207538 | Enhanced Production of Functional Proteins From Defective Genes - This invention provides methods for enhancing production in a subject of a functional protein from a gene disrupted by a mutation, for example by the presence of a premature stop codon or by an exon skipping mutation, comprising administering to the subject an amount of an agent effective to suppress the mutation and an amount of an agent effective to increase transcription of the gene. | 2008-08-28 |
20080207539 | Self-Processing Rna Expression Cassette - The invention provides a self-processing RNA expression cassette which includes at least one pair of processing units, an RNAi effecter sequence of predetermined length that regulates target gene expression which is flanked by said pair of processing units; and at least one pair of cognate ribozyme cis-cleavage target sites located 5′ and 3′ of the RNAi effecter sequence. The self-processing RNA expression cassette is able to express in vivo and in vitro and the RNAi effecter sequence includes at least one target recognition sequence derived from the Hepatitis B Virus (HBV) X gene (HBx). | 2008-08-28 |
20080207540 | Method For the Identification of Compounds Modulating Reverse Transport of Cholesterol - The invention relates to methods and compounds which can modulate reverse cholesterol transport in a mammal and to screening methods enabling the selection, identification and/or characterization of compounds which can modulate reverse cholesterol transport. The invention also relates to cells, vectors and genetic constructs which can be used to implement said methods, in addition to pharmaceutical compositions intended for the treatment of atherosclerosis. | 2008-08-28 |
20080207541 | Compositions and Methods For Optimizing Cleavage of Rna By Rnase H - The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3′hydroxy thereof, to the region bound to the 5′ hydroxyl thereof. | 2008-08-28 |
20080207542 | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce diseases, traits and conditions that are associated with gene expression or activity in a subject or organism. | 2008-08-28 |
20080207543 | MODIFIED PITUITARY GLAND DEVELOPMENT IN OFFSPRING FROM EXPECTANT MOTHER ANIMALS TREATED WITH GROWTH HORMONE RELEASING HORMONE THERAPY - The intramuscular electroporated injection of a protease-resistant growth hormone-releasing hormone (“GHRH”) cDNA into rat dams at 16 days of gestation resulted in the enhanced long-term growth of the FI offspring. The offspring were significantly heavier by one week of age and the difference was sustained to 10 weeks of age. Consistent with their augmented growth, plasma IGF-I concentration of the FI progeny was increased significantly. The pituitary gland of the offspring was significantly heavier, and contained an increased number of somatotropes (cells producing GH) and lactotrophs (prolactin-secreting cells), and is indicative of an alteration in cell lineages. These unique findings demonstrate that enhanced GHRH expression in pregnant dams can result in intergenerational growth promotion, by altering development of the pituitary gland in the offspring. | 2008-08-28 |
20080207544 | Compositions And Methods For Delivery Of Agents Into Cells - Disclosed herein are novel compositions for delivery of biologically active agents into cells comprising a cationic amphiphile and a complementary lipid composition. Also disclosed are methods of making and using such novel compositions. | 2008-08-28 |
20080207545 | Methods and Compositions for Treating 5Alpha-Reductase Type 1 and Type 2 Dependent Conditions - The invention relates generally to the use of anti-sense oligonucleotides, small interfering RNA, and ribozymes to modulate expression of the human steroid 5α-reductase gene and thereby modulate levels of dihydrotestosterone (DHT). Elevated levels of DHT are associated with various disorders including, but not limited to, skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia. The invention specifically relates to formulations of these anti-sense oligonucleotides, small interfering RNA, and ribozymes for administration to treat and prevent disorders | 2008-08-28 |
20080207546 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | 2008-08-28 |
20080207547 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-08-28 |
20080207548 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-08-28 |
20080207549 | GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA - The present application provides novel human genes WDRPUH and KRZFPUH and PPIL1 whose expression is markedly elevated in a great majority of HCC's and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target for developing drugs against the disease. | 2008-08-28 |
20080207550 | IMMUNOMODULATORY POLYNUCLEOTIDES AND METHODS OF USING THE SAME - The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides. | 2008-08-28 |
20080207551 | MODIFIED OLIGONUCLEOTIDES CONTAINING DIPHOSPHODIESTER INTERNUCLEOTIDE LINKAGES - The synthesis and biochemical utility of modified oligonucleotides containing diphosphodiester internucleotide linkages. The synthesis of these compounds was carried out using diphosphitylating reagents. Oligonucleotides containing diphosphate diester bridges wherein said oligonucleotides are synthesized via a solid-phase synthesis strategy to form modified oligonucleotides. Diphosphitylating, triphosphitylating, tetraphosphitylating, β-triphosphitylating, bifunctional diphosphitylating, bifunctional triphosphitylating, and bifunctional tetraphosphitylating reagents wherein, the phosphorus atoms are linked together through oxygen, sulfur, amino, or methylene groups and/or are substituted with chlorine, diisopropylamine and cyanoethoxy groups. | 2008-08-28 |
20080207552 | Decoy compositions for treating and preventing brain diseases and disorders - The present invention provides introduction of NF-κB decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-κB decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor α, interleukin 1β and intracellular adhesion molecule 1 messenger RNAs. Terminal deoxynucleotidyl transferase-mediated deoxyuridine nick-end labeling staining and immunohistochemistry using microtubule-associated protein 2 demonstrated that transfected NF-κB decoy oligodeoxynucleotide significantly attenuated neuronal damage seven days after global brain ischemia. Therapeutic transfection of NF-κB decoy oligodeoxynucleotide during brain ischemia may be effective for attenuation of neuronal damage, suggesting a strategy for protecting the cerebrum from global ischemia. | 2008-08-28 |
20080207553 | Biodegradable Cationic Polymers - Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells. | 2008-08-28 |
20080207554 | 2-5A Analogs and their Methods of Use - This invention relates to the fields of organic chemistry, pharmaceutical chemistry, biochemistry, molecular biology and medicine. In particular it relates to compounds that activate RNaseL, and to the use of the compounds for treating and/or ameliorating a disease or a condition, such as a viral infection. | 2008-08-28 |
20080207555 | HYDROLASE AND METHODS FOR ITS USE - This disclosure provides methods for catalyzing the release of ADP-ribose from poly(ADP-ribose) or O-acetyl-ADP-ribose. Also provided are methods for modifying DNA repair or chromatin structure by introducing into the cell an agent that modifies the activity of an ARH3 polypeptide, or variant or fragment thereof. Further provided are methods for screening molecules involved in the poly(ADP-ribosyl)ation of proteins or O-acetyl-ADP-ribose content, and method for treating disorders by altering activity of an ARH3 protein. | 2008-08-28 |
20080207556 | Product and Process for Inhibition of Biofilm Development - Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions. | 2008-08-28 |
20080207557 | Methods of Decreasing or Preventing Pain Using Spicamycin Derivatives - Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided. | 2008-08-28 |
20080207558 | Process for the Preparation of Trivalent Iron Complexes with Mono-, Di- and Polysaccharide Sugars - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0. | 2008-08-28 |
20080207559 | Carbohydrates mixture - A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed, | 2008-08-28 |
20080207560 | Composition For External Use - An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. | 2008-08-28 |
20080207561 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME - A novel biomaterial is disclosed having unique properties that make it useful in ocular drug delivery applications, where the drugs selected from the group consisting of a prostaglandin, a prostamide, a non-steroidal anti-inflammatory drug (NSAID), and a corticosteroid, and mixtures, derivatives, salts and esters thereof. | 2008-08-28 |
20080207562 | Conjugates of Hydroxyalkyl Starch and Active Substance, Prepared by Chemical Ligation Via Thiazolidine - The present invention relates to a method for preparing conjugates of an active substance and hydroxyalkyl starch and to conjugates of an active substance and hydroxyalkyl starch, preferably hydroxyethyl starch, wherein the conjugates are prepared by covalently linking the hydroxyalkyl starch and the active substance by a chemical residue having a structure according to formula (I) | 2008-08-28 |
20080207563 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS - Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human. | 2008-08-28 |
20080207564 | Derivaitves of 4-Or 5-Aminosalicylic Acid - The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer. | 2008-08-28 |
20080207565 | USE OF BISPHOSPHONATES FOR PAIN TREATMENT - A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient | 2008-08-28 |
20080207566 | Methods for the administration of amifostine and related compounds - The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration. | 2008-08-28 |
20080207567 | Treatment of Hcv Disorders - S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). | 2008-08-28 |
20080207568 | Class of Gamma Delta T Cells Activators and Use Thereof - The present invention relates to a new class of compounds having γδ T cells activating properties referred to herein as angelyl or tiglyl phosphoesters, compositions comprising any of these compounds and methods for regulating an immune response in a subject comprising the step of administering these compounds. | 2008-08-28 |
20080207569 | Methods for the treatment of liver diseases - Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by administering the matrix metalloproteinase inhibitor. | 2008-08-28 |
20080207570 | Topically applicable oil-in-water emulsions and dermatological applications thereof - Novel topically applicable oil-in-water emulsions, with a high proportion of oily phase in the inner phase, combine the occlusive and emollient properties of an ointment without having the drawbacks of a greasy feel, while at the same time promoting the therapeutic properties of a biologically active agent contained therein; such emulsions are especially useful for the treatment of dermatological diseases, conditions or afflictions, notably psoriasis. | 2008-08-28 |
20080207571 | Regimens for Oral Monophasic Contraceptives - The subject invention provides for new regimens for monophasic oral contraceptives. | 2008-08-28 |
20080207572 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma - The present invention relates to a method for treating Multiple Myeloma (MM), FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual C-KIT/FGFR3 inhibitor, such as 2-aminoarylthiazoles and 2-aminoaryloxazoles. | 2008-08-28 |
20080207573 | COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2008-08-28 |
20080207574 | WITHANOLIDES, PROBES AND BINDING TARGETS AND METHODS OF USE THEREOF - Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics by extracting proteins from cells that were exposed to withanolide-biotin analog. The withanolide probes can be used to monitor expression of vimentin, in tumor samples or other diseased tissues. Withaferin analogs can be used as a treatment for diverse vimentin-associated disorders, such as cancers, angiofibrotic diseases, and chronic inflammation. | 2008-08-28 |
20080207575 | Process For The Preparation Of Drospirenone - A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising the oxidation of 17α-(3-hydroxypropyl)-6β,7β,15β,16β-dimethylene-5β-androstane-3β,5,17β-triol. | 2008-08-28 |
20080207576 | Substituted sapogenins and their use - The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed | 2008-08-28 |
20080207577 | Combination I - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a P2X | 2008-08-28 |
20080207578 | METHOD OF INDUCING APOPTOSIS IN CANCER TREATMENT BY USING CUCURBITACINS - This invention relates to the preparation and use of anti-cancer compounds/formulation containing cucurbitacins. Said formulation comprises active ingredients, particularly cucurbitacin B and cucurbitacin D, with the efficacy of anti-proliferation and inducing cellular apoptosis. Said formulation owns the anticancer activity. This invention also provides a method of isolating and purifying the active ingredients in lab-scale and in industrial-scale. | 2008-08-28 |
20080207579 | Uses of tetrahydrobiopterin and derivatives thereof - The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor. | 2008-08-28 |
20080207580 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 2008-08-28 |
20080207581 | Methods and systems for coating a surface - A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying a coating to a surface. The coating may be antimicrobial. A coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface. | 2008-08-28 |
20080207582 | Substituted Porphyrins - A series of ortho isomers of meso tetrakis N-alkylpyridylporphyrins (alkyl being methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl) and their Mn(III) complexes were synthesized and characterized by elemental analysis, uv/vis spectroscopy, electrospray ionization mass spectrometry and electrochemistry. An increase in the number of carbon atoms in the alkyl chains from 1 to 8 is accompanied by an increase in: (a) lipophilicity measured by the chromatographic retention factor, R | 2008-08-28 |
20080207583 | Process For Preparing Granulates Comprising Amoxicillin - A novel process for preparing a stable granulate, which comprises a mixture of amoxicillin trihydrate and amoxicillin sodium, by means of extrusion granulation of amoxicillin trihydrate with an aqueous solution of sodium hydroxide, sodium bicarbonate, sodium carbonate and mixture thereof or with an aqueous solution of sodium salt of (C | 2008-08-28 |
20080207584 | Compound Having S1P Receptor Binding Potency and Use Thereof - Provided are: a compound represented by formula (I): | 2008-08-28 |
20080207585 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof - The present invention provides compounds represented by the structural formula (I): | 2008-08-28 |
20080207586 | Novel crystal form of pyrrolidylthiocarbapenem derivative - A novel crystal of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction preferably having main peaks at diffraction angles (2θ)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) is provided. | 2008-08-28 |
20080207587 | Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a arc defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. | 2008-08-28 |
20080207588 | Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines - The present invention is concerned with certain novel derivatives of Formula I, | 2008-08-28 |
20080207589 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS - The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: | 2008-08-28 |
20080207590 | Inhibitors of Histone Deacetylase - This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) | 2008-08-28 |
20080207591 | Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 2008-08-28 |
20080207592 | Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof - The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic. | 2008-08-28 |
20080207593 | Antihistamine Combination - A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at bed-time has demonstrated greater efficacy in relieving allergic symptoms than Loratadine alone. | 2008-08-28 |
20080207594 | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders - This invention relates to the use of Pax4 stimulating compounds, e.g. Glycogen synthase kinase-3 (GSK-3) inhibitors, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I diabetes or LADA. More particularly, this invention relates to the use of compounds selected from paullones, indirubines, substituted ureas, maleimide derivatives and pyrimidine thiones. Further, the present invention relates to a method of identifying and/or characterizing pancreatic beta-cell mitogens by using cells expressing a pancreatic gene or a gene whose function is controlled by a pancreatic gene, particularly the Pax4 gene, and which are transfected with a reporter gene. | 2008-08-28 |
20080207595 | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin -
The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II):
| 2008-08-28 |
20080207596 | Novel compounds 329 - The invention concerns a compound of formula (I) | 2008-08-28 |
20080207597 | HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE OF SARS CORONAVIRUS - Provided is a homopiperazine compound for inhibiting ribosomal frameshifting by binding to an RNA pseudoknot structure of SARS coronavirus. Particularly, the present invention provides a pharmaceutical composition for inhibiting synthesis of protein induced by −1 frameshifting by binding to an RNA pseudoknot structure specifically existing in SARS coronavirus. The composition includes a therapeutically effective amount of homopiperazine compound of following chemical formula 1 or a pharmaceutically accepted salt thereof, and a pharmaceutically accepted carrier or excipient. | 2008-08-28 |
20080207598 | INDOLE DERIVATIVES - The invention relates to indole derivative having the general Formula I | 2008-08-28 |
20080207600 | Pharmaceutical Combination for the Treatment of Cns Functional Disorders - The invention relates to a method and a pharmaceutical combination for the treatment of CNS disorders, which includes at least a first compound having therapeutic effect on the CNS, and a second compound which facilitates penetration through the hematoencephalic barrier of the former. The second compound is administered endonasally, and has refectory (mainly neuro- and vasoactive) effects over structures and receptors of nasal mucous membrane, mainly receptors of vomeronasal systems and trifacial nerve. | 2008-08-28 |
20080207601 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence - Compositions for reducing dependency and addiction to substances of abuse are provided. Chloride channels such as the GABA | 2008-08-28 |
20080207602 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION - This invention relates to novel lactams having the formula (I): | 2008-08-28 |
20080207603 | Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc) - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. Wherein: each of R | 2008-08-28 |
20080207604 | Materials and methods relating to protein aggregation in neurodegenerative disease - The present invention relates to methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheiemer's disease. | 2008-08-28 |
20080207605 | Combination therapy for the treatment of liver diseases - Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and caspase inhibitors described herein. Further provided are methods for lowering an elevated level of liver enzymes. | 2008-08-28 |
20080207606 | Novel heterocycles - Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases. | 2008-08-28 |
20080207607 | Heterotricyclic metalloprotease inhibitors - The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors. | 2008-08-28 |
20080207608 | 2-Propene-1-Ones As Hsp 70 Inducers - The present invention relates to novel compounds of 2-propene-1-one series, of general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, wherein R | 2008-08-28 |
20080207609 | Pharmaceutical compounds - Fused pyrimidines of formula (I): | 2008-08-28 |
20080207610 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 2008-08-28 |
20080207611 | Pharmaceutical compounds - Fused pyrimidines of formula (I): | 2008-08-28 |
20080207612 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof - Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R | 2008-08-28 |
20080207613 | Selective Kinase Inhibitors - A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C | 2008-08-28 |
20080207614 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY - The present invention relates to novel quinazoline derivatives effective in lowering blood glucose level and body weight, and a medicine for treatment and/or prevention of diabetes and/or obesity, which comprises the compound as an active ingredient. | 2008-08-28 |
20080207615 | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments - The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug. | 2008-08-28 |
20080207616 | Quinoxalines as B Baf Inhhibitors - The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 2008-08-28 |
20080207617 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same - An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: | 2008-08-28 |
20080207618 | 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor - The present invention relates to a compound represented by the following formula [I] | 2008-08-28 |
20080207619 | Diaminopyrimidines as P2X3 and P2X2/3 modulators - Compounds and methods for treating diseases mediated by a P2X | 2008-08-28 |
20080207620 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV, | 2008-08-28 |
20080207621 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases. | 2008-08-28 |
20080207622 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are sulfone compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases. | 2008-08-28 |
20080207623 | Peptide-enhanced corneal drug delivery - Improved methods and preparations are provided for ocular administration of therapeutic drugs. The preparations include respective quantities of a drug and a peptide which enhances transport of the drug across ocular tissues. The drug and peptide components may be separately administered or used as a mixture. The preferred peptide is NC-1059 (Seq. ID No. 1). | 2008-08-28 |
20080207624 | Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia - A pharmaceutical preparation containing sapropterin hydrochloride can be used to administer sapropterin hydrochloride, an effective therapeutic agent for the treatment of tetrahydrobiopterin-responsive hyperphenylalaninemia, to patients of a wide range of ages, ranging from infants to adults, in a single preparation. One specific example is a pharmaceutical preparation for the treatment of BH4-responsive hyperphenylalaninemia provided in the form of granule, fine granule, or dry syrup, comprising sapropterin hydrochloride as an active ingredient; a flavoring agent; a coloring agent which is stable to acid and oxidation; and ascorbic acid or L-cysteine hydrochloride as a stabilizer, wherein the preparation has a moisture content (weight loss on drying) of 0.9% or less. Also provided is the pharmaceutical preparation in which the amount of sapropterin hydrochloride is from 2.5 to 20 wt %. | 2008-08-28 |